To develop more effective drugs against GBCs, we selected 29 compounds (approved for clinical use by the food‐and‐drug‐administration (FDA)) targeting signalling pathways commonly activated in tumours and assessed their viability to suppress the viability of GBC organoids, for example, MAPK, Janus Kinase‐signal transducer and activator of transcription (JAK‐STAT), receptor tyrosine kinase and HDAC inhibitors (Figure 5A, Table S2). This evidence concerns the gene NTRK1 and neoplasm.